

# CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY IN NON-SMALL-CELL LUNG CANCER TREATED WITH NIVOLUMAB




A. Codonal Demetrio, I. Mendoza Acosta, M. Blanco Crespo, Gl. Casarrubios Lázaro, E. Martínez, P. Tardáguila Molina, A. Miranda del Cerro, LE. Chara Velarde, P. De Juan-García Torres. Hospital Pharmacy, Hospital Emergency Department. Guadalajara, Spain.



## BACKGROUND AND IMPORTANCE

Nivolumab, an immune checkpoint inhibitor, has shown a relationship between immune-related adverse events (irAEs) and efficacy in different studies, although these are not very consistent.



## AIM AND OBJECTIVES

To assess the association between irAEs and the efficacy of nivolumab in adults with locally advanced or metastatic non-small cell lung cancer (mNSCLC) after prior chemotherapy.

## MATERIALS AND METHODS



Restrospective observational study



August 2015- June 2022

- ✓ **Data collected:** demographic (age, sex) and clinical (histology, smoking habit, performance status (ECOG), line of treatment, response to previous chemotherapy and irAEs).
- ✓ **Overall survival (OS) and progression-free survival (PFS) analysis** was performed using Kaplan Meier. The association between irAEs and OS were analyzed by Cox Regression.

## RESULTS




- **67 patients** (88% men)
- Median age at the beginning of treatment: **67 years** (IQR: 59-75)

- ☐ ECOG 0-1: 52%
- ☐ Second line treatment: 73%
- ☐ Histology squamous: 40%
- ☐ Disease Control Rate: 78%
- ☐ Former smokers/Smokers/Non-smokers: 53%/39%/8%

irAEs type	N=28 irAEs (22 patients)	HR (95% CI)	p
Pneumonitis	10	0.62 (0.3-1.3)	0.2
<b>Endocrine</b>	<b>6</b>	<b>0.23 (0.1-0.7)</b>	<b>0.014</b>
Gastrointestinal	6	0.59 (0.2-1.6)	0.3
<b>Skin</b>	<b>6</b>	<b>0.2 (0.1-0.7)</b>	<b>0.008</b>

	irAE	Non-irAE
<b>OS</b> (months) (95% CI; p<0,05)	<b>12.1</b> (7.9-16.3)	<b>4.4</b> (1.9-7.0)
<b>PFS</b> (months) (95% CI; p<0,05)	<b>8.7</b> (0-41.2)	<b>3.3</b> (1.9-4.7)



## CONCLUSION AND RELEVANCE

- ✓ In this study our data suggest a relationship between irAEs and increased OS, specially endocrine and skin.
- ✓ As our study was observational, other features as sex, ECOG or smoking habit that could bias results were not balanced between the study groups.

No conflict of interest

Abstract number: 4CPS-088

L01- ANTINEOPLASTIC AGENTS

